[Prospective controlled study of elective sclerotherapy plus oral propranolol for prevention of recurrent bleeding in cirrhotics with recent variceal hemorrhage].
In a prospective, randomized controlled trial, 43 patients with cirrhosis and variceal hemorrhage were allocated after control of the bleeding to treat by elective sclerotherapy alone (n = 23) or by oral propranolol after elective sclerotherapy (n = 20). The dose of oral propranolol was based on a reduction of the resting pulse rate by 25%. The end points of the study were rebleeding or death. Both treatment groups were comparable with respect to origin and severity of liver disease, size of esophageal varices and portal pressure at entry. The mean follow up was 27 +/- 19 months for all patients. Patients treated sclerotherapy alone had more rebleeding (n = 11) did than those in the sclerotherapy plus propranolol (n = 3). The cumulative percentages of patients free of rebleeding 1 and 2 years after inclusion were 77 and 66% in sclerotherapy alone, and 100 and 85% in sclerotherapy plus propranolol; the difference between the two groups was significant. No statistically significant effect on mortality was seen. These data support that oral propranolol after sclerotherapy reduces the risk of recurrent bleeding in cirrhotics treated elective sclerotherapy.
Kanazawa
H
H
Third Department of Internal Medicine, Nippon Medical School.
Watari
A
A
Matsusaka
S
S
Tada
N
N
Miyata
K
K
Saitoh
H
H
Yoshizawa
M
M
Kuroda
H
H
Kobayashi
M
M
D000284:Administration, Oral; D004932:Esophageal and Gastric Varices / Q000628:therapy*; D006471:Gastrointestinal Hemorrhage / Q000517:prevention & control*; D006503:Hepatic Veins / Q000503:physiopathology; D006801:Humans; D008103:Liver Cirrhosis / Q000503:physiopathology / Q000628:therapy*; D011433:Propranolol / Q000008:administration & dosage*; D011446:Prospective Studies; D012008:Recurrence; D012422:Rupture, Spontaneous; D015911:Sclerotherapy; D014690:Venous Pressure
D011433:Propranolol